Trial Profile

A phase I two-part, double-blinded, randomized, placebo-controlled trial to evaluate CMX-2043

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CMX 2043 (Primary)
Indications Traumatic brain injuries
Focus Adverse reactions; Pharmacokinetics
Sponsors Ischemix

Most Recent Events

25 Aug 2023 According to a Ischemix media release, trial funded in part by an award granted to Ischemix by US Army Medical Research and Development Command (USAMRDC), Combat Casualty Care Research Program (CCCRP), in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501 biomedical technology consortium.
25 Aug 2023 According to a Ischemix media release, Altasciences Company performed the Phase 1 trial at its Montreal, Quebec, Canada facility.
25 Aug 2023 Results presented in a Ischemix media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com